Takanori Matsui

マツイタカノリ | Takanori Matsui

Affiliation and department：

Research field (4)： Food sciences , Chemical biology , Laboratory animal science , Cell biology

Research keywords (9)： physiologically functional food , Advanced Glycation End-products , Pigment Epithelium Derived Factor , peptide , aptamer , insulin resistance , diabetic complication , 細胞生物学 , Cell Biology

Research theme for competitive and other funds (14)：

2023 - 2026 Development of an Innovative Therapy Utilizing RAGE Aptamer to Achieve Zero Mortality in Neonatal Necrotizing Enterocolitis.
2023 - 2026 Development of a novel therapeutic approach for diabetic nephropathy by nucleic acid medicine (DNA aptamer).
2022 - 2025 内因性一酸化炭素COの産生調節機構の解明と新規メディカルガスによる治療基盤の構築
2019 - 2022 Identification of structures of advanced glycation end-products responsible for proatherosclerotic effects - analysis using aptamers.
2019 - 2022 Post-translational modifications regulating the activity and function of carbon monoxide synthase

Show all

Papers (230)：

Yuta Nakamura, Ichiro Horie, Tadahiro Kitamura, Yoshiki Kusunoki, Kenro Nishida, Akane Yamamoto, Yushi Hirota, Tomoyasu Fukui, Yasutaka Maeda, Masae Minami, et al. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study. Diabetes, obesity & metabolism. 2024
Yosuke Ochi, Takanori Matsui, Keitaro Inoue, Kohei Monobe, Hiroshi Sakamoto, Shunsuke Aoki, Junichi Taira. Computational Screening and Experimental Validation of Inhibitor Targeting the Complex Formation of Grb14 and Insulin Receptor. Molecules. 2023. 29. 1. 298
Yusaku Mori, Makoto Ohara, Michishige Terasaki, Naoya Osaka, Hironori Yashima, Tomomi Saito, Yurie Otoyama-Kataoka, Takemasa Omachi, Yuichiro Higashimoto, Takanori Matsui, et al. Subcutaneous Infusion of DNA-Aptamer Raised against Advanced Glycation End Products Prevents Loss of Skeletal Muscle Mass and Strength in Accelerated-Aging Mice. Biomedicines. 2023. 11. 12. 3112-3112
Akihiro Honda, Nobuhiro Tahara, Atsuko Tahara, Munehisa Bekki, Shoko Maeda-Ogata, Yoichi Sugiyama, Sachiyo Igata, Yuri Nishino, Takanori Matsui, Seiji Kurata, et al. Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. Journal of Nuclear Cardiology. 2023. 30. 4. 1613-1626
Michishige Terasaki, Keita Shibata, Yusaku Mori, Tomomi Saito, Takanori Matsui, Makoto Ohara, Tomoyasu Fukui, Keiji Hasumi, Yuichiro Higashimoto, Koji Nobe, et al. SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis. International Journal of Molecular Sciences. 2023. 24. 7. 6505-6505

ｍore...

MISC (198)：

古賀義法, 外川内亜美, 東元祐一郎, 西野友梨, 松井孝憲, 角間辰之, 秋葉純, 田中芳明, 八木実, 加治建, et al. 終末糖化産物受容体を阻害するRAGEアプタマーは敗血症マウスの生存率を改善する. 日本抗加齢医学会総会プログラム・抄録集. 2023. 23rd
寺崎道重, 柴田佳太, 柴田佳太, 森雄作, 斎藤智美, 松井孝憲, 八島広典, 大坂直也, 藤川大輝, 高畑洋, et al. SMTP-44DはApoE欠損マウスの動脈硬化進展を抑制する. 日本抗加齢医学会総会プログラム・抄録集. 2023. 23rd
古賀義法, 外川内亜美, 東元祐一郎, 西野友梨, 松井孝憲, 角間辰之, 秋葉純, 八木実, 加治建, 山岸昌一. 終末糖化産物受容体を阻害するDNAアプタマーは敗血症マウスの生存率を改善する. 外科と代謝・栄養. 2022. 56. 3. 74-74
外川内亜美, 東元祐一郎, 古賀義法, 西野友梨, 松井孝憲, 山岸昌一. DNAアプタマーによる終末糖化産物受容体の阻害は老年疾患を包括的に抑制する. 日本抗加齢医学会総会プログラム・抄録集. 2022. 22回. 220-220
松井孝憲, 東元祐一郎, 山岸昌一. 終末糖化産物(AGEs)の阻害による老年病の包括的抑制. 日本抗加齢医学会総会プログラム・抄録集. 2022. 22回. 253-253

ｍore...

Patents (3)：

Education (4)：

2000 - 2004 Kyushu Institute of Technology
1997 - 2000 Kyushu Institute of Technology
1995 - 1997 Kyushu Institute of Technology School of Computer Science and Systems Engineering
1990 - 1995 National Institute of Technology, Fukui College

Professional career (1)：

(BLANK)

Association Membership(s) (7)：

Japanese Society of Food Chemistry , 日本抗加齢医学会 , JAPANESE SOCIETY OF NEPHROLOGY , THE MOLECULAR BIOLOGY SOCIETY OF JAPAN , NUCLEIC ACIDS THERAPEUTICS SOCIETY OF JAPAN , THE JAPAN DIABETES SOCIETY , The Japanese Biochemical Society

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page